The current financial score of aTyr Pharma Ord Shs is 8.57. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 189.56M, representing a year-over-year increase of 113.35%, while its net profit experienced a year-over-year increase of 5.75%.
The current valuation score of aTyr Pharma Ord Shs is 8.85. Its current P/E ratio is -13.83, which is -294.53% below the recent high of 26.90 and -15.44% above the recent low of -15.96.
The current earnings forecast score of aTyr Pharma Ord Shs is 8.89. The average price target is 34.57, with a high of 40.00 and a low of 32.00.
The current price momentum score of aTyr Pharma Ord Shs is 4.98. Currently, the stock price is trading between the resistance level at 42.02 and the support level at 31.31, making it suitable for range-bound swing trading.
The current institutional shareholding score of aTyr Pharma Ord Shs is 7.00. The latest institutional shareholding proportion is 88.45%, representing a quarter-over-quarter increase of 43.25%.
The current risk assessment score of aTyr Pharma Ord Shs is 3.68. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.